MTT-Based Assessment of the Anticancer Potential of a Known 1,2-Disubstituted Benzimidazole Compound on DLD-1 Cell Line

Year 2025, Volume: 3 Issue: 2, 73 - 77, 25.11.2025

Yasemin Sunucu Karafakıoğlu , Elif Ece Akgün , İkbal Demet Nane , Senem Akkoç

https://doi.org/10.70500/bjs.1799229

Abstract

In this study, the cytotoxic effect of 1-(4-methylbenzyl)-2-p-tolyl-1H-benzo[d]imidazole (SL-13) was investigated on human colorectal cancer DLD-1 cells using the MTT assay. Treatment with SL-13 at various concentrations (100, 50, and 25 µM) for 72 hours resulted in a potent cytotoxic response with an IC₅₀ value of 6.093 µM, indicating strong antiproliferative activity. This potency surpasses that reported for many other benzimidazole derivatives tested against DLD-1 cells. These findings show that SL-13 is a promising candidate for further development in colorectal cancer therapy, warranting additional mechanistic and in vivo studies to elucidate its therapeutic potential.

Keywords

Benzimidazole , Colorectal Cancer , Cytotoxic Activity , DLD-1

Ethical Statement

As this research was conducted entirely on established cancer cell lines, ethics committee approval was not required.

Supporting Institution

Süleyman Demirel University

Project Number

TSG-2024-9516

Thanks

SA would like to thank the Suleyman Demirel University Research Fund for financial support with project number TSG-2024-9516.

DLD-1 Hücre Hattında Bilinen 1,2-Disübstitüe Benzimidazol Bileşiğinin Antikanser Potansiyelinin MTT Bazlı Değerlendirilmesi

Abstract

Bu çalışmada, 1-(4-metilbenzil)-2-p-tolil-1H-benzo[d]imidazolün (SL-13) sitotoksik etkisi, MTT testi kullanılarak insan kolorektal kanser DLD-1 hücreleri üzerinde araştırılmıştır. SL-13 ile çeşitli konsantrasyonlarda (100, 50 ve 25 µM) 72 saat boyunca uygulanan tedavi, 6,093 µM'lik bir IC₅₀ değeriyle güçlü bir sitotoksik yanıta yol açmış ve bu da güçlü antiproliferatif aktiviteye işaret etmiştir. Bu etki, DLD-1 hücrelerine karşı test edilen diğer birçok benzimidazol türevi için bildirilen etkiyi aşmaktadır. Bu bulgular, SL-13'ün kolorektal kanser tedavisinde daha fazla geliştirilmeye aday olduğunu göstermekte ve terapötik potansiyelini aydınlatmak için ek mekanistik ve in vivo çalışmalara ihtiyaç duyulmaktadır.

Keywords

Benzimidazol , Kolorektal Kanser , Sitotoksik Aktivite , DLD-1

Ethical Statement

Bu araştırma tamamen yerleşik kanser hücre hatları üzerinde yürütüldüğünden etik kurul onayına gerek duyulmamıştır.

Supporting Institution

Süleyman Demirel Üniversitesi

Project Number

TSG-2024-9516

Thanks

SA, TSG-2024-9516 numaralı projeyle sağladığı finansal destekten dolayı Süleyman Demirel Üniversitesi Araştırma Fonu'na teşekkür etmek ister.

References

• Ahmad, N., Azad, M., Khan, A., & Azad, I. (2021). Benzimidazole as a promising antiviral heterocyclic Scaffold: A review. Journal of Science and Arts, 21(1), 273–284.
• Akkoc, S., Kayser, V., İlhan, İ. Ö., Hibbs, D. E., Gök, Y., Williams, P. A., ... & Lai, F. (2017). New compounds based on a benzimidazole nucleus: synthesis, characterization and cytotoxic activity against breast and colon cancer cell lines. Journal of Organometallic Chemistry, 839, 98-107.
• Akkoc, S., Sahin, D., Muhammed, M. T., Yıldız, M., & Ilhan, I. O. (2023). Synthesis, characterization, antiproliferative activity, docking, and molecular dynamics simulation of new 1,3-dihydro-2H-benzimidazol-2-one derivatives. Journal of Biomolecular Structure and Dynamics, 42(21), 11495–11507.
• Akkoç, S. (2021). Design, synthesis, characterization, and in vitro cytotoxic activity evaluation of 1, 2‐disubstituted benzimidazole compounds. Journal of Physical Organic Chemistry, 34(1), e4125.
• Al-Douh, M. H., Sahib, H. B., Osman, H., Abd Hamid, S., & Salhimi, S. M. (2012). Anti-proliferation effects of benzimidazole derivatives on HCT-116 colon cancer and MCF-7 breast cancer cell lines. Asian Pacific journal of cancer prevention : APJCP, 13(8), 4075–4079.
• Al-Nasser, S., Abdulla, M. H., Alhassan, N., Vaali-Mohammed, M. A., Al-Omar, S., Hamdi, N., Elnakady, Y., Matou-Nasri, S., & Mansour, L. (2024). A Benzimidazole-Based N-Heterocyclic Carbene Derivative Exhibits Potent Antiproliferative and Apoptotic Effects against Colorectal Cancer. Medicina (Kaunas, Lithuania), 60(9), 1379.
• Ansari, K. F., & Lal, C. (2009). Synthesis and evaluation of some new benzimidazole derivatives as potential antimicrobial agents. European journal of medicinal chemistry, 44(5), 2294–2299.
• Bayar, I., Turkmenoglu, B., & Akkoc, S. (2024). Biological and in Silico Studies on the Benzimidazole-Based Compounds. Chemistry Africa, 7(5), 2345-2352.
• Bui, H. T. B., Htoo, Z. P., Hong, Q. V., Le, H. T., Tran, Q., Hnin, S. Y. Y., Do, K. M., & Morita, H. (2024). Facile Synthesis of 1,2-Disubstituted Benzimidazoles as Potent Cytotoxic Agents. Chemical & pharmaceutical bulletin, 72(11), 944–949.
• Dienstmann, R., Rodon, J., Barretina, J., & Tabernero, J. (2013). Genomic medicine frontier in human solid tumors: prospects and challenges. Journal of Clinical Oncology, 31(15), 1874-1884.
• Gök, Y., Akkoc, S., Çelikal, Ö. Ö., Özdemir, İ., & Günal, S. (2019). In vitro antimicrobial studies of naphthalen-1-ylmethyl substituted silver N-heterocyclic carbene complexes. Arabian Journal of Chemistry, 12(8), 2513-2518.
• Haque, R. A., Ghdhayeb, M. Z., Budagumpi, S., Salman, A. W., Ahamed, M. B. K., & Majid, A. M. S. A. (2013). Non-symmetrically substituted N-heterocyclic carbene–Ag (I) complexes of benzimidazol-2-ylidenes: Synthesis, crystal structures, anticancer activity and transmetallation studies. Inorganica Chimica Acta, 394, 519-525.
• He, L. J., Yang, D. L., Li, S. Q., Zhang, Y. J., Tang, Y., Lei, J., Frett, B., Lin, H. K., Li, H. Y., Chen, Z. Z., & Xu, Z. G. (2018). Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells. Bioorganic & medicinal chemistry, 26(14), 3899–3908.
• Kumar, R., Marianesan, A. B., & Pathak, S. (2024). Benzimidazole as a Privileged Scaffold in Drug Design and Discovery. Current topics in medicinal chemistry, 24(17), 1504–1528.
• Moharana, A. K., Dash, R. N., Mahanandia, N. C., & Subudhi, B. B. (2022). Synthesis and anti-inflammatory activity evaluation of some benzimidazole derivatives. Pharmaceutical Chemistry Journal, 56(8), 1070–1074.
• Shrivastava, N., Naim, M. J., Alam, M. J., Nawaz, F., Ahmed, S., & Alam, O. (2017). Benzimidazole Scaffold as anticancer agent: Synthetic approaches and structure–activity relationship. Archiv Der Pharmazie, 350(6), e201700040.
• Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
• Tumosienė, I., Peleckis, A., Jonuškienė, I., Vaickelionienė, R., Kantminienė, K., Šiugždaitė, J., ... & Mickevičius, V. (2018). Synthesis of novel 1, 2-and 2-substituted benzimidazoles with high antibacterial and antioxidant activity. Monatshefte für Chemie-Chemical Monthly, 149(3), 577-594.
• Venugopal, S., Kaur, B., Verma, A., Wadhwa, P., Magan, M., Hudda, S., & Kakoty, V. (2023). Recent advances of benzimidazole as anticancer agents. Chemical biology & drug design, 102(2), 357–376.
• Yavuz S. C. (2024). Synthesis of new two 1,2-disubstituted benzimidazole compounds: their in vitro anticancer and in silico molecular docking studies. BMC chemistry, 18(1), 146.